NFL Biosciences (XPAR:ALNFL) Debt-to-EBITDA : -0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NFL Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.06 Mil. NFL Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. NFL Biosciences's annualized EBITDA for the quarter that ended in Dec. 2023 was €-3.53 Mil. NFL Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NFL Biosciences's Debt-to-EBITDA or its related term are showing as below:

XPAR:ALNFL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.31 Med: -0.06 Max: -0.02
Current: -0.02

During the past 6 years, the highest Debt-to-EBITDA Ratio of NFL Biosciences was -0.02. The lowest was -0.31. And the median was -0.06.

XPAR:ALNFL's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.36 vs XPAR:ALNFL: -0.02

NFL Biosciences Debt-to-EBITDA Historical Data

The historical data trend for NFL Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Debt-to-EBITDA Chart

NFL Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.31

-0.10

-0.03

-0.02

NFL Biosciences Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			N/A	-0.03	-0.03	-0.03	-0.02

Competitive Comparison of NFL Biosciences's Debt-to-EBITDA

For the Biotechnology subindustry, NFL Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's Debt-to-EBITDA falls into.

NFL Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NFL Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.062	+	0)	/	-4.049
	=	-0.02

NFL Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.062	+	0)	/	-3.534
	=	-0.02

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

NFL Biosciences (XPAR:ALNFL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NFL Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (XPAR:ALNFL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

82F:Germany

Address

199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170

Website

https://www.nflbiosciences.com/

NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines